Tempest Therapeutics (TPST) Change in Accured Expenses (2012 - 2025)

Tempest Therapeutics has reported Change in Accured Expenses for 14 years, with the latest figure at $3.1 million in Q3 2025.

• Quarterly Change in Accured Expenses rose 13608.7% year-over-year to $3.1 million in Q3 2025, while the trailing twelve-month figure through Dec 2025 was -$59000.0 (down 9.26% YoY) and the FY2025 annual result came in at -$59000.0, down 9.26% from the prior year.
• Change in Accured Expenses climbed to $3.1 million in Q3 2025 per TPST's latest filing, from -$3.1 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $3.1 million in Q3 2025 and troughed at -$3.1 million in Q2 2025.
• A 5-year average of -$33578.9 and a median of -$23000.0 in 2024 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2024 and 2025: Change in Accured Expenses sank 14400.0% in 2024, then soared 13608.7% in 2025.
• Over 5 years, Change in Accured Expenses stood at $634000.0 in 2021, then tumbled by 144.64% to -$283000.0 in 2022, then sank by 253.71% to -$1.0 million in 2023, then jumped by 97.6% to -$24000.0 in 2024, then soared by 13045.83% to $3.1 million in 2025.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered $3.1 million, -$3.1 million, and -$23000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.